Novo Nordisk Aktie

Novo Nordisk für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 866931 / ISIN: US6701002056

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
14.08.2024 12:00:00

This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock

It's not often that a biotech wins when a big pharma stumbles, but Madrigal Pharmaceuticals (NASDAQ: MDGL) is now in a better place than before because of a setback at Danish drug giant Novo Nordisk (NYSE: NVO). The two cardiometabolic drug developers will avoid direct competition for the time being, and now, any head-to-head match up in the future could favor Madrigal a bit more than before.But is the biotech still a buy? Let's clarify the question by looking at what just happened and why it matters.In its second-quarter earnings update for investors, Novo Nordisk disclosed a surprising failure. One of its programs, a unique investigational therapy for metabolic-associated steatohepatitis (MASH, formerly known as NASH), would be terminated immediately. The corresponding phase 1 clinical trial has already been halted well before its completion, and, by the looks of it, there are not any plans to try to revive the program at a later date.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Novo Nordisk (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Madrigal Pharmaceuticals Inc. 295,60 -0,40% Madrigal Pharmaceuticals Inc.
Novo Nordisk (spons. ADRs) 62,20 -1,58% Novo Nordisk (spons. ADRs)